Tempus AI announced an expansion of its collaboration with Takeda, a global pharmaceutical company, to enhance Takeda’s oncology research and development efforts. This agreement builds upon an initial collaboration that utilized Tempus’ de-identified multimodal datasets.
Under the expanded agreement, Takeda will combine Tempus’ multimodal real-world datasets and biological modeling capabilities to advance its pipeline of cancer therapeutics, which includes antibody-drug conjugates, small molecules, bispecifics, and gamma delta T-cell therapies. Takeda researchers will use Tempus’ analytics platform, Lens, to gain real-time access to de-identified patient records and AI-enabled tools.
The collaboration also involves a multi-phase biological modeling project, leveraging Tempus’ repository of patient-derived tumor organoids. This project will use a panel of 60 organoids spanning 10 cancer indications to functionally evaluate several preclinical candidates, aiming to enhance the predictability of drug effectiveness and guide early drug candidate prioritization.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.